相关实验视频

Updated: Sep 19, 2025

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

在局部晚期胃癌中接受新辅助疗法后,HER2表达的演变

Jun He¹, Hongming Liu¹, Yansong Dong¹

¹Department of Surgery, Second Affiliated Hospital of School of Medicine, Zhejiang University, Hangzhou 310058, China.

|June 16, 2025

概括

在胃癌患者接受新辅助治疗 (NAT) 后,HER2表达的变化很常见. 在NAT后降低HER2表达与更好的生存相关,强调需要重新评估.

科学领域:

在瘤学瘤学.
胃肠病学胃肠病学
生物标志物研究生物标志物研究

背景情况:

HER2是胃癌的关键生物标志物,影响治疗和预后.
新辅助治疗 (NAT) 是局部晚期胃癌的标准治疗方法.
了解NAT后的HER2表达动态对于优化治疗至关重要.

研究的目的:

在局部晚期胃癌中接受新辅助治疗后,研究HER2表达变化的频率和模式.
确定影响HER2表达变化的因素后NAT.
评估HER2表达变化的预后意义以及治疗对这些变化的影响.

主要方法:

在398名局部晚期胃癌患者的多中心回顾性研究中.
患者接受了新辅助治疗 (NAT),随后进行胃切除 (2018-2023年).
分析HER2表达变化,临床结果和治疗影响.

主要成果:

超过40%的患者在NAT后表现出HER2表达的改变,表达的减少 (26.0%) 比表达的增加 (17.3%) 更频繁.
诊断时的HER2状态显著预测了变化;HER2 IHC 2+瘤显示出更高的变化趋势.
在NAT后降低HER2表达与改善无复发和整体存活率有关.
PD-1/PD-L1 抑制剂和特拉斯图祖马布增加了pCR率,但在非pCR患者中没有显著改变HER2表达变化.

结论:

在胃癌中接受新辅助治疗后,HER2表达通常会发生变化.
在NAT后重新评估HER2状态对于指导针对HER2的疗法至关重要.
在NAT之后HER2表达减少是一个有利的预后指标.

关键词:

在瘤学瘤学.治疗方法治疗方法

更多相关视频

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

相关概念视频

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...